Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Mallinckrodt Plc (NYSE:MNK)

55.97
Delayed Data
As of Jun 24
 -2.75 / -4.68%
Today’s Change
50.90
Today|||52-Week Range
127.00
-25.00%
Year-to-Date
Trending Tickers: UAL, MNK, ENDP, BWA
Jun 21 / TheStreet.com - Paid Partner Content
Mallinckrodt Needs More Medicine
Jun 20 / TheStreet.com - Paid Partner Content

Today’s Trading

Previous close58.72
Today’s open55.98
Day’s range55.65 - 57.82
Volume2,416,130
Average volume (3 months)2,512,584
Market cap$6.1B
Dividend yield--
Data as of 4:01pm ET, 06/24/2016

Growth & Valuation

Earnings growth (last year)--
Earnings growth (this year)+12.30%
Earnings growth (next 5 years)+9.75%
Revenue growth (last year)+31.75%
P/E ratio17.0
Price/Sales2.40
Price/Book1.23

Competitors

 Today’s
change
Today’s
% change
TAROTaro Pharmaceutical ...-4.56-3.18%
ALKSAlkermes Plc-1.47-3.36%
VRXValeant Pharmaceutic...-1.98-8.90%
SGENSeattle Genetics Inc-2.48-6.19%
Data as of 4:02pm ET, 06/24/2016

Financials

Next reporting dateAugust 4, 2016
EPS forecast (this quarter)$2.00
Annual revenue (last year)$3.3B
Annual profit (last year)$322.1M
Net profit margin9.13%

Profile

Sector
Health Technology
Industry
Pharmaceuticals: Other
President, Chief Executive Officer &
Director
Mark C. Trudeau
Senior Vice President-
Global Operations
Frank Scholz
Corporate headquarters
Chesterfield, Derbyshire

Forecasts

Partner Offers

Search for Jobs